Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company focused on developing therapies to treat oncology and inflammation-based diseases, skyrocketed as much as 32% after reporting top-line data from a proof-of-concept trial involving ruxolitinib for refractory metastatic pancreatic cancer.

So what: In its phase 2a trial, Incyte Corporation (NASDAQ:INCY) notes that ruxolitinib — its oral JAK1 and JAK2 inhibitor that’s currently approved to treat myelofibrosis under the trade name Jakafi — when combined with Roche‘s Xeloda demonstrated a hazard ratio for overall survival in the intent to treat population of 0.79. In a pre-specified subgroup that was expected to benefit most from JAK pathway inhibition, the hazard ratio for overall survival was 0.47, with six-months survival at 42% for the ruxolitinib arm compared to just 11% for the placebo. Also, only patients in the ruxolitinib arm showed durable tumor response and significant improvement in body weight.

Now what: As you can tell by today’s move higher, this is incredibly good early stage news for advanced metastatic pancreatic sufferers. Furthermore, it appears that Incyte Corporation (NASDAQ:INCY) has already honed in on which subgroups would benefit most by JAK pathway inhibition, meaning that a companion diagnostic test may be unnecessary. Jakafi delivered improved overall survivial in a phase 3 myelofibrosis trial, which lends hope that ruxolitinib to treat metastatic prostate cancer will do the same. With regard to Incyte Corporation (NASDAQ:INCY), I’d love to see a pullback from today’s pop but would certainly understand if it didn’t.

Not to be forgotten in this as well is Novartis AG (ADR) (NYSE:NVS), which has full licensing rights to ruxolitinib outside the United States. If things continue to go well for ruxolitinib it’ll mean less lost sleep at night for Novartis AG (ADR) (NYSE:NVS) shareholders who are looking for new therapies to take the reins as patent expirations sweep through the pharmaceutical industry.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.

Subscribe me to Insider Monkey's Free Daily Newsletter

This is a FREE report from Insider Monkey. Credit Card is NOT required.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.